PURPOSE: To determine whether a Protected Graft Copolymer (PGC) containing fatty acid can be used as a stabilizing excipient for GLP-1 and whether PGC/GLP-1 given once a week can be an effective treatment for diabetes. METHODS: To create a PGC excipient, polylysine was grafted with methoxypolyethyleneglycol and fatty acid at the epsilon amino groups. We performed evaluation of the binding of excipient to GLP-1, the DPP IV sensitivity of GLP-1 formulated with PGC as the excipient, the in vitro bio-activity of excipient-formulated GLP-1, the in vivo pharmacokinetics of excipient-formulated GLP-1, and the efficacy of the excipient-formulated GLP-1 in diabetic rats. RESULTS: We showed reproducible synthesis of PGC excipient, high affinity binding of PGC to GLP-1, slowed protease degradation of excipient-formulated GLP-1, and that excipient-formulated GLP-1 induced calcium influx in INS cells. Excipient-formulated GLP-1 stays in the blood for at least 4 days. When excipient-formulated GLP-1 was given subcutaneously once a week to diabetic ZDF rats, a significant reduction of HbA1c compared to control was observed. The reduction is similar to diabetic ZDF rats given exendin twice a day. CONCLUSIONS: PGC can be an ideal in vivo stabilizing excipient for biologically labile peptides.
PURPOSE: To determine whether a Protected Graft Copolymer (PGC) containing fatty acid can be used as a stabilizing excipient for GLP-1 and whether PGC/GLP-1 given once a week can be an effective treatment for diabetes. METHODS: To create a PGC excipient, polylysine was grafted with methoxypolyethyleneglycol and fatty acid at the epsilon amino groups. We performed evaluation of the binding of excipient to GLP-1, the DPP IV sensitivity of GLP-1 formulated with PGC as the excipient, the in vitro bio-activity of excipient-formulated GLP-1, the in vivo pharmacokinetics of excipient-formulated GLP-1, and the efficacy of the excipient-formulated GLP-1 in diabeticrats. RESULTS: We showed reproducible synthesis of PGC excipient, high affinity binding of PGC to GLP-1, slowed protease degradation of excipient-formulated GLP-1, and that excipient-formulated GLP-1 induced calcium influx in INS cells. Excipient-formulated GLP-1 stays in the blood for at least 4 days. When excipient-formulated GLP-1 was given subcutaneously once a week to diabetic ZDFrats, a significant reduction of HbA1c compared to control was observed. The reduction is similar to diabetic ZDFrats given exendin twice a day. CONCLUSIONS: PGC can be an ideal in vivo stabilizing excipient for biologically labile peptides.
Authors: John B Buse; Julio Rosenstock; Giorgio Sesti; Wolfgang E Schmidt; Eduard Montanya; Jason H Brett; Marcin Zychma; Lawrence Blonde Journal: Lancet Date: 2009-06-08 Impact factor: 79.321
Authors: Bidda Rolin; Marianne O Larsen; Carsten F Gotfredsen; Carolyn F Deacon; Richard D Carr; Michael Wilken; Lotte Bjerre Knudsen Journal: Am J Physiol Endocrinol Metab Date: 2002-10 Impact factor: 4.310
Authors: Sandra Reichstetter; Gerardo M Castillo; Israel Rubinstein; Akiko Nishimoto-Ashfield; Manshun Lai; Cynthia C Jones; Aryamitra A Banerjee; Aryamitra Banjeree; Alex Lyubimov; Duane C Bloedow; Alexei Bogdanov; Elijah M Bolotin Journal: Pharm Res Date: 2012-12-07 Impact factor: 4.200
Authors: Gerardo M Castillo; Akiko Nishimoto-Ashfield; Aryamitra A Banerjee; Jennifer A Landolfi; Alexander V Lyubimov; Elijah M Bolotin Journal: Pharm Res Date: 2013-06-21 Impact factor: 4.200
Authors: Christian W Grant; Catherine M Moran-Paul; Shane K Duclos; Dennis L Guberski; Guillermo Arreaza-Rubín; Lisa M Spain Journal: PLoS One Date: 2013-08-30 Impact factor: 3.240
Authors: Gerardo M Castillo; Akiko Nishimoto-Ashfield; Cynthia C Jones; Kasim K Kabirov; Alexander Zakharov; Alexander V Lyubimov Journal: PLoS One Date: 2017-02-16 Impact factor: 3.240